{"id":"NCT02059161","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)","officialTitle":"A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-17","primaryCompletion":"2015-05-04","completion":"2015-11-12","firstPosted":"2014-02-11","resultsPosted":"2017-03-08","lastUpdate":"2018-09-05"},"enrollment":508,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"MK-1293","otherNames":[]},{"type":"DRUG","name":"Lantus™","otherNames":["Insulin glargine"]},{"type":"DRUG","name":"Prandial Insulin","otherNames":[]}],"arms":[{"label":"MK-1293","type":"EXPERIMENTAL"},{"label":"Lantus","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of MK-1293 to Lantus™ in participants with T1DM. The primary hypothesis is that after 24 weeks, the mean change in hemoglobin A1c (A1C) from baseline is non-inferior in participants treated with MK-1293 compared with participants treated with Lantus™.","primaryOutcome":{"measure":"Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"MK-1293","deltaMin":-0.62,"sd":null},{"arm":"Lantus","deltaMin":-0.66,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":25},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29766635"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":241},"commonTop":["Hypoglycaemia","Upper respiratory tract infection","Nasopharyngitis"]}}